بدائل البحث:
significant case » significant cause (توسيع البحث), significant based (توسيع البحث), significant change (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
case based » made based (توسيع البحث), game based (توسيع البحث), rate based (توسيع البحث)
significant case » significant cause (توسيع البحث), significant based (توسيع البحث), significant change (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
case based » made based (توسيع البحث), game based (توسيع البحث), rate based (توسيع البحث)
-
41
-
42
-
43
Significantly Enriched Pathways.
منشور في 2025"…By comparing samples from NAFLD patients and healthy controls, we identified 1,770 significant DEGs, with 1,073 being upregulated and 697 downregulated. …"
-
44
-
45
Base-case results.
منشور في 2024"…Clinical findings have showed that deprescribing service significantly decreased inappropriate PPIs utilization. …"
-
46
-
47
The base case analysis.
منشور في 2025"…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …"
-
48
-
49
Base-case results.
منشور في 2025"…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …"
-
50
-
51
Base-case analysis.
منشور في 2023"…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …"
-
52
Temporal profiles of the key BO-NN features.
منشور في 2020"…The shifts associated with non-significant prediction accuracies are greyed-out. <b>(c)</b> The results of the MDS for the key BO-NN features. …"
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60